Artelo Biosciences, Inc. (ARTL) stock
ARTLNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.50−0.18 (-10.71%)
Close on Nov 18, 2026Market cap $1.01MP/E –Yield –
Artelo Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Artelo Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$11.07M. For fiscal 2025 it was -$11.40M. The highest annual figure on record is -$15.24K in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.40M | – |
| FY2024 | Dec 31, 2024 | -$10.11M | – |
| FY2023 | Dec 31, 2023 | -$9.93M | – |
| FY2021 | Aug 31, 2021 | -$7.44M | – |
| FY2020 | Aug 31, 2020 | -$4.69M | – |
| FY2019 | Aug 31, 2019 | -$3.21M | – |
| FY2018 | Aug 31, 2018 | -$2.34M | – |
| FY2017 | Aug 31, 2017 | -$232.79K | – |
| FY2016 | Aug 31, 2016 | -$29.69K | – |
| FY2015 | Aug 31, 2015 | -$15.24K | – |
| FY2014 | Aug 31, 2014 | -$15.27K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$2.51M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$2.69M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$2.79M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$3.09M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$3.15M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$2.38M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$3.81M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$1.20M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$2.51M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$2.59M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$3.24M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$2.61M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$1.78M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$2.29M | – |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | -$1.89M | – |
| Q3 FY2021CQ2 2021 | May 31, 2021 | -$2.25M | – |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | -$1.87M | – |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | -$1.44M | – |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | -$1.03M | – |
| Q3 FY2020CQ2 2020 | May 31, 2020 | -$951.40K | – |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | -$1.37M | – |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | -$1.34M | – |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | -$953.42K | – |
| Q3 FY2019CQ2 2019 | May 31, 2019 | -$941.29K | – |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | -$757.92K | – |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | -$556.90K | – |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | -$690.11K | – |
| Q3 FY2018CQ2 2018 | May 31, 2018 | -$577.86K | – |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | -$798.46K | – |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | -$277.06K | – |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | -$115.55K | – |
| Q3 FY2017CQ2 2017 | May 31, 2017 | -$95.73K | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | -$12.00K | – |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | -$9.52K | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | -$4.33K | – |
| Q3 FY2016CQ2 2016 | May 31, 2016 | -$5.05K | – |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | -$5.09K | – |
| Q1 FY2016CQ4 2015 | Nov 30, 2015 | -$15.22K | – |
| Q4 FY2015CQ3 2015 | Aug 31, 2015 | -$4.59K | – |
| Q3 FY2015CQ2 2015 | May 31, 2015 | -$2.50K | – |
See a number that looks wrong?